Vilazodone: A novel antidepressant.
Purpose. The pharmacology and pharmacokinetics of the antidepressant vilazodone (approved for U.S. marketing in 2011) are reviewed, with an emphasis on efficacy and safety data from Phase III clinical trials. Summary. Vilazodone (marketed as Viibryd by Forest Pharmaceuticals) is a dualacting seroton...
| Publicado en: | American Journal of Health-System Pharmacy Vol. 69; no. 18; pp. 1551 - 1558 |
|---|---|
| Autores principales: | , , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Oxford University Press / USA
9/15/2012
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104503326&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104503326 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10792082 1X3 jtl: American Journal of Health-System Pharmacy issn: 10792082 maglogo: N pubinfo: dt: 9/15/2012 vid: 69 iid: 18 pid: 622 pub: Oxford University Press / USA artinfo: ui: 104503326 79722679 10.2146/ajhp110374 NLM22935937 104503326 ppf: 1551 ppct: 7 formats: fmt: @attributes: type: P tig: atl: Vilazodone: A novel antidepressant. aug: au: Choi, Elizabeth Zmarlicka, Monika Ehret, Megan J. affil: Postgraduate Year 1 Pharmacy Resident, Northport Veterans Affairs Medical Center, Northport, NY sug: subj: Heterocyclic Compounds Therapeutic Use Indoles Therapeutic Use Depression Drug Therapy Antidepressive Agents Therapeutic Use Treatment Outcomes Clinical Trials Antidepressive Agents Pharmacodynamics Antidepressive Agents Pharmacokinetics Antidepressive Agents Administration and Dosage Antidepressive Agents Adverse Effects Serotonin Uptake Inhibitors Therapeutic Use ab: Purpose. The pharmacology and pharmacokinetics of the antidepressant vilazodone (approved for U.S. marketing in 2011) are reviewed, with an emphasis on efficacy and safety data from Phase III clinical trials. Summary. Vilazodone (marketed as Viibryd by Forest Pharmaceuticals) is a dualacting serotonergic agent that combines the antidepressant effects of a selective serotonin-reuptake inhibitor (SSRI) with partial serotonin (5-HT)1A-receptor agonist activity. In two published eight-week Phase III trials involving a total of 878 adults with major depressive disorder (MDD), vilazodone use was found to yield significant symptomatic improvements relative to placebo use, as determined by mean changes from baseline in scores on the Hamilton Depression Rating Scale and other widely used clinical assessment instruments. Vilazodone hydrochloride therapy should be initiated at a dosage of 10 mg once daily and incrementally adjusted over 14 days to the recommended target daily dose of 40 mg; for optimal bioavailability and effectiveness, it should be taken after a light or high-fat meal. The adverse effects most commonly reported in clinical trials of vilazodone were diarrhea, nausea, vomiting, and insomnia. Conclusion. Vilazodone is an efficacious and safe new antidepressant for the treatment of MDD. Its relatively high cost and adverse-effect profile, as well as a lack of data demonstrating that vilazodone can produce long-term MDD remission and offer significant advantages over the current standard of care, may limit the usefulness of vilazodone in clinical practice. pubtype: Academic Journal doctype: review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|